In this study, competitive inhibitors of KMT2A could reduce PU.1 expression by inhibiting KMT2A complex, and showed therapeutic effects in bleomycin‐induced pulmonary fibrosis in mice. Here, SPI1 is linked to pulmonary fibrosis.